Intersect ENT Inc. (NASDAQ:XENT) shares fell 4.6% on Thursday . The stock traded as low as $15.04 and last traded at $15.62, with a volume of 323,981 shares traded. The stock had previously closed at $16.37.

Several research firms have recently weighed in on XENT. Canaccord Genuity reaffirmed a “buy” rating and set a $20.00 price objective on shares of Intersect ENT in a research report on Thursday. BTIG Research reaffirmed a “hold” rating and set a $14.00 price objective on shares of Intersect ENT in a research report on Thursday. Wedbush reaffirmed an “outperform” rating and set a $25.00 price objective on shares of Intersect ENT in a research report on Wednesday. Finally, Zacks Investment Research raised Intersect ENT from a “sell” rating to a “hold” rating in a research report on Wednesday, May 11th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Intersect ENT presently has an average rating of “Buy” and a consensus price target of $25.00.

The firm’s market cap is $439.86 million. The stock’s 50 day moving average is $14.24 and its 200-day moving average is $16.28.

Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.05. The business earned $19.30 million during the quarter, compared to the consensus estimate of $18.91 million. The business’s revenue was up 27.0% on a year-over-year basis. During the same period last year, the business posted ($0.23) earnings per share. Equities research analysts forecast that Intersect ENT Inc. will post ($0.98) EPS for the current fiscal year.

In other news, VP James Stambaugh sold 5,000 shares of Intersect ENT stock in a transaction dated Monday, July 18th. The stock was sold at an average price of $15.33, for a total value of $76,650.00. Following the completion of the transaction, the vice president now directly owns 29,000 shares of the company’s stock, valued at approximately $444,570. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Kieran Gallahue acquired 8,000 shares of the stock in a transaction dated Monday, May 16th. The stock was acquired at an average cost of $12.64 per share, with a total value of $101,120.00. Following the completion of the transaction, the director now owns 8,000 shares in the company, valued at approximately $101,120. The disclosure for this purchase can be found here.

Several hedge funds and institutional investors have bought and sold shares of XENT. Jennison Associates LLC raised its position in Intersect ENT by 11.2% in the fourth quarter. Jennison Associates LLC now owns 2,770,905 shares of the company’s stock valued at $62,345,000 after buying an additional 279,176 shares during the period. Wells Fargo & Company MN raised its stake in shares of Intersect ENT by 36.2% in the fourth quarter. Wells Fargo & Company MN now owns 2,288,725 shares of the company’s stock worth $51,495,000 after buying an additional 607,788 shares during the last quarter. RS Investment Management Co. LLC raised its stake in shares of Intersect ENT by 68.2% in the fourth quarter. RS Investment Management Co. LLC now owns 1,328,250 shares of the company’s stock worth $29,886,000 after buying an additional 538,720 shares during the last quarter. Royce & Associates LLC raised its stake in shares of Intersect ENT by 15.7% in the fourth quarter. Royce & Associates LLC now owns 420,400 shares of the company’s stock worth $9,459,000 after buying an additional 56,900 shares during the last quarter. Finally, Schroder Investment Management Group purchased a new stake in shares of Intersect ENT during the fourth quarter worth approximately $6,845,000.

Intersect ENT, Inc is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.